Question special
Chief Resident

In the United States, alteplase may be started prior to patient transfer to a specialty center, whereby endovascular thrombectomy may be attempted. This may lead to alteplase infusion finishing prior to endovascular thrombectomy. However, in the trial, only 23 of 319 patients had their infusion completed prior to thrombectomy. What is the significance of this to the authors? Could this explain the lack of clinical benefit seen between the two groups, despite pretreatment with alteplase leading to successful reperfusion in higher numbers than in the thrombectomy alone group? Thank you!